Allchem Lifescience IPO
Allchem Lifescience IPO is a Mainboard book-built issue comprising a Fresh Issue of up to ₹190 crore and an Offer for Sale of up to 71,55,000 equity shares. The face value of the equity shares is ₹10 per share. The price band, lot size and IPO dates are y
Allchem Lifescience IPO Details
Allchem Lifescience IPO is a proposed Mainboard book-built issue comprising a Fresh Issue of up to ₹190 crore and an Offer for Sale of up to 71,55,000 equity shares by promoter selling shareholders. The company filed its Draft Red Herring Prospectus with SEBI in March 2025 and subsequently issued an Addendum to the DRHP. The equity shares are proposed to be listed on BSE and NSE. The IPO price band, bidding dates, allotment date and listing date are yet to be announced.
Allchem Lifescience IPO Timeline (Tentative)
Allchem Lifescience IPO bidding dates, basis of allotment, refund, credit to Demat and listing dates have not yet been announced. The company has filed its DRHP and subsequent Addendum, while the final IPO schedule will be disclosed before the public issue opens.
| Event | Tentative Date |
|---|---|
| IPO Opens | |
| IPO Closes | |
| Basis of Allotment | |
| Refund Initiation | |
| Credit of Shares to Demat | |
| Listing Date |
Allchem Lifescience IPO Lot Size
The Allchem Lifescience IPO lot size and minimum investment amount have not yet been announced. The number of shares per application lot and the corresponding investment amount will be available after the company announces the IPO price band and minimum bid lot.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | |||
| Retail (Max) | |||
| S-HNI (Min) | |||
| S-HNI (Max) | |||
| B-HNI (Min) |
Allchem Lifescience IPO Reservation
Allchem Lifescience IPO provides for not more than 50% of the Offer to be available for allocation to Qualified Institutional Buyers. The Non-Institutional portion will be not less than 15% of the Offer, while the Retail Individual Investor portion will be not less than 35% of the Offer, subject to the applicable SEBI regulations and final offer documents.
Allchem Lifescience IPO Subscription
Allchem Lifescience IPO subscription details will be available once the issue opens for public bidding. The category-wise subscription will cover QIB, NII and RII participation along with the overall subscription level.
| Category | Subscription (times) |
|---|---|
| QIB | |
| NII | |
| RII | |
| Total |
About Allchem Lifescience
Allchem Lifescience Limited is a manufacturer of active pharmaceutical ingredient intermediates and speciality chemicals. The company specialises in key starting materials, generic API intermediates and specialty chemicals used across pharmaceutical and other chemical applications. The business was originally established as Allchem Laboratories in 2003 and was later acquired by Allchem Lifescience Private Limited in 2017. The company was converted into a public limited company in 2024.
The company operates manufacturing facilities focused on a wide range of chemical reactions and products. Its product portfolio includes API intermediates, specialty chemicals, custom synthesis and contract manufacturing. The company has developed particular capabilities in piperazine derivatives and other pharmaceutical intermediates and caters to customers in pharmaceutical, specialty chemical, electrochemical, agrochemical and biotechnology industries.
Allchem Lifescience serves both domestic and international markets. During the six months ended September 30, 2024, the company generated revenue from exports to customers across overseas markets, including Europe, China, Japan and other regions. As of December 31, 2024, the company had exported its products to 22 countries.
The company has expanded its manufacturing capacity over the years. Its first manufacturing facility had a capacity of 36 KL and was commissioned in 2013, while the capacity was subsequently expanded to 174 KL. The company has also undertaken further expansion to support new chemistries, product development and increasing customer requirements. The company states that its facilities are supported by quality systems and certifications, including ISO certifications and third-party GMP certification, and that it underwent a US FDA inspection in 2024.
Strengths
- Manufacturer of API intermediates, key starting materials and speciality chemicals serving pharmaceutical and chemical industries.
- • Diversified product capabilities covering pharmaceuticals, specialty chemicals, electrochemical, agrochemical and biotechnology applications.
- • Established manufacturing and process-development capabilities with experience in multiple chemical reactions.
- • Presence in international markets with products exported to 22 countries as of December 31, 2024.
- • Consistent financial performance, with revenue from operations growing at a CAGR of 12.75% between FY2022 and FY2024.
- • Strong improvement in profitability, with PAT growing at a CAGR of 28.67% between FY2022 and FY2024.
Risks to Consider
- The company depends significantly on certain key customers, and changes in relationships with major customers may affect revenue.
- • Revenue from operations is concentrated in certain geographical markets, creating exposure to regional business conditions.
- • The company operates in the competitive pharmaceutical intermediates and specialty chemicals industry.
- • The business is exposed to fluctuations in raw-material prices, manufacturing costs and other operating expenses.
- • The company has significant borrowings, and changes in interest rates or cash flows could affect its financial performance.
- • The company has disclosed a legal dispute concerning the use of the “Allchem” name and trademark, which may require a change in branding or could result in associated costs and business implications.
Allchem Lifescience Financials (₹ Cr)
Allchem Lifescience reported revenue from operations of ₹108.10 crore in FY2022, ₹105.72 crore in FY2023 and ₹137.42 crore in FY2024. Profit after tax stood at ₹14.14 crore in FY2022, ₹17.99 crore in FY2023 and ₹23.41 crore in FY2024. For the six months ended September 30, 2024, the company reported revenue from operations of ₹78.45 crore and PAT of ₹10.89 crore.
| Period | Revenue | PAT | Total Assets | Net Worth |
|---|---|---|---|---|
| FY2022 | 108.10 | 14.14 | 124.02 | 38.58 |
| FY2023 | 105.72 | 17.99 | 186.68 | 56.49 |
| FY2024 | 137.42 | 23.41 | 224.65 | 79.89 |
| 6M FY2025 | 78.45 | 10.89 | 246.30 | 90.74 |
KPIs & Valuation
Allchem Lifescience reported basic and diluted EPS of ₹3.06 for FY2024. The company reported a NAV per share of ₹10.44 and RoNW of 34.33% for FY2024. The FY2024 EBITDA margin was 38.05%, while PAT margin stood at 17.03%. The Pre-IPO P/E and Post-IPO P/E cannot be calculated until the company announces the final IPO price band.
Objects of the Issue
The proposed Fresh Issue of up to ₹190 crore is primarily intended to reduce the company's outstanding borrowings. The company proposes to use ₹130 crore from the Net Proceeds for repayment or pre-payment, in full or in part, of certain outstanding borrowings. The remaining proceeds are proposed to be used for general corporate purposes and other business requirements. The company will not receive any proceeds from the Offer for Sale. The company proposes to utilise the Net Proceeds for:
- Repayment or pre-payment, in full or in part, of certain outstanding borrowings availed by the company.
- General corporate purposes.
- Meeting the business requirements of the company.
Promoters, Lead Managers & Registrar
Allchem Lifescience Limited is promoted by Bipin Patel, Kantilal Ramanlal Patel, Aditi Patel and Manisha Bipin Patel. Emkay Global Financial Services Limited is the sole Book Running Lead Manager to the Offer. MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, is the Registrar to the Offer.
Promoters
Lead Managers (BRLM)
Registrar
| Name | MUFG Intime India Private Limited |
|---|---|
| Phone | +91 8108114949 |
| allchemlifescience.ipo@in.mpms.mufg.com | |
| Website | https://www.in.mpms.mufg.com/ |
Allchem Lifescience IPO Review
Allchem Lifescience operates in the pharmaceutical intermediates and specialty chemicals segment, with capabilities covering key starting materials, generic API intermediates and specialty chemicals. The company serves customers across pharmaceutical and other chemical-related industries and has developed capabilities in multiple chemical reactions and specialised products.
The company has reported consistent financial growth in the periods covered by its DRHP. Revenue from operations increased from ₹108.10 crore in FY2022 to ₹137.42 crore in FY2024, representing a CAGR of 12.75%. Profit after tax increased from ₹14.14 crore in FY2022 to ₹23.41 crore in FY2024, while the company reported ₹78.45 crore revenue and ₹10.89 crore PAT during the six months ended September 30, 2024.
The proposed Fresh Issue is expected to provide funds for reducing borrowings. The company plans to use ₹130 crore of the Net Proceeds for repayment or pre-payment of certain outstanding borrowings, with the balance intended for general corporate purposes. The proposed use of funds is therefore directly connected with reducing the company's debt burden and supporting its business requirements.
However, investors should consider customer concentration, geographical concentration, competition, raw-material and operating-cost fluctuations and borrowing-related risks. The company has also disclosed litigation relating to the use of the “Allchem” name. Since the final price band has not yet been announced, the IPO valuation and P/E-based assessment cannot be determined at this stage.
How to Apply
Allchem Lifescience IPO applications can be made through ASBA or UPI once the issue opens for subscription. The IPO price band, bidding dates and lot size have not yet been announced.
Through UPI
- Log in to your stockbroker app/website.
- Go to the IPO section.
- Select Allchem Lifescience IPO once the issue opens.
- Enter the number of lots you want to apply for.
- Select the bid price.
- Enter your valid UPI ID.
- Submit the IPO application.
- Open your UPI app when the mandate request arrives.
- Approve the mandate using your UPI PIN.
- The application amount will be blocked in your bank account. If shares are allotted, the required amount will be debited; otherwise, the blocked amount will be released.
Prospectus & Documents
Investors can refer to the company's Draft Red Herring Prospectus, Addendum to the DRHP and subsequent offer documents for detailed information about the business, financial performance, risk factors, IPO structure and utilisation of the issue proceeds. The company has made the IPO offer documents available through its official website.
Last updated Sep 28, 2026.